Redcliffe Labs announced the launch of the Elecsys® AMH Plus blood test, in collaboration with Roche Diagnostics India, to support the timely identification of Polycystic Ovarian Morphology (PCOM) and aid in the diagnosis of Polycystic Ovary Syndrome (PCOS).
Nearly one in five women of reproductive age in India is affected by PCOS. To address this growing concern, Redcliffe Labs, through the Elecsys® AMH Plus test, is transforming the diagnostic experience. Instead of relying on invasive scans, a simple blood test now measures Anti-Müllerian Hormone (AMH), a biomarker closely associated with PCOM and found in nearly four out of five PCOS cases in India.
This innovation replaces the discomfort and limitations of transvaginal ultrasounds (TVUS) with a convenient, reliable solution that offers a minimally invasive test for a patient-friendly diagnosis. The test results are accurate across body types, and it can be performed at any time without waiting for specific menstrual phases.
The Elecsys® AMH Plus test is supported by strong global and Indian validation. International guidelines (2023) now recognize AMH as a credible alternative to ultrasound for evaluating PCOM, while in India, FOGSI’s Good Clinical Practice Recommendations endorse its role in PCOS diagnosis. Large clinical studies such as APHRODITE and HARMONIA confirm its high accuracy, with a 3.2 ng/mL cutoff, achieving 89% sensitivity and 85% specificity.
Aditya Kandoi, Founder & CEO of Redcliffe Labs, added: “PCOS remains one of the most widespread yet underdiagnosed health issues for women. With this innovative test, we are breaking diagnostic barriers and enabling timely, accurate care and empowering women through proactive health solutions that redefine their reproductive and metabolic journeys.”
Dr. Rishubh Gupta, MD, Roche Diagnostics India, added, “By introducing the Elecsys® AMH Plus blood test, Redcliffe Labs is making PCOS diagnostics more accessible and less intimidating. This reinforces our commitment to bridging healthcare gaps by consistently bringing Roche’s world-class clinical innovations to the Indian market.”
